Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb — a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn — for U.S. preparedness against Ebola disease. Regeneron expects to deliver additional treatment doses through 2031 and receive payment of approximately $270 million.
Agreement Snapshot
| Item | Detail |
|---|---|
| Parties | Regeneron (NASDAQ: REGN) & BARDA / ASPR, U.S. HHS |
| Action | Extension of existing Inmazeb supply agreement |
| Product | Inmazeb — atoltivimab + maftivimab + odesivimab-ebgn (three-mAb cocktail) |
| Purpose | U.S. national preparedness stockpile against Ebola disease |
| Delivery Period | Through 2031 |
| Contract Value | ~USD 270 million |
| Announcement Date | 26 Oct 2026 |
Drug Profile – Inmazeb
- Composition: A fully human monoclonal antibody combination targeting the Ebola virus glycoprotein at three distinct epitopes — atoltivimab, maftivimab, and odesivimab-ebgn — a design intended to limit viral escape through mutation.
- Regulatory Status: The first Ebola treatment approved by the U.S. FDA.
- Indication: Infection caused by Orthoebolavirus zairense (Zaire ebolavirus) in adult and pediatric patients, including neonates born to infected mothers.
- Real-World Use: Administered to hundreds of patients since 2019, spanning outbreak response and therapeutic use in affected regions.
Pipeline Expansion – Bundibugyo Virus Program
- Monotherapy Candidate: Separate from the procurement agreement, Regeneron is evaluating maftivimab — the most potent virus-neutralizing component of Inmazeb — as a potential treatment for Ebola disease caused by Bundibugyo virus, a distinct ebolavirus species not covered by Inmazeb’s current Zaire-specific label.
- Strategic Rationale: Broadening from single-species (Zaire) to multi-species (Bundibugyo) coverage would expand Regeneron’s position in the filovirus therapeutic space and address recurring outbreak threats from non-Zaire strains.
Market Impact & Outlook
- Durable Revenue Visibility: The ~$270 million extension through 2031 locks in long-dated government-backed revenue for a product with otherwise episodic, outbreak-driven demand.
- Stockpile Model: BARDA’s continued procurement reinforces the U.S. strategy of maintaining pre-positioned Ebola countermeasures, validating Regeneron’s preparedness-franchise approach.
- Pipeline Optionality: The maftivimab Bundibugyo program adds potential label-expansion upside beyond the existing Zaire indication.
- Platform Validation: Inmazeb’s decade-plus deployment record strengthens the case for Regeneron’s multi-antibody cocktail platform in other high-consequence infectious disease threats.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the BARDA agreement extension, Inmazeb deliveries through 2031, and the evaluation of maftivimab for Bundibugyo virus Ebola disease. Actual results may differ due to risks including delivery schedules, government funding and procurement decisions, clinical outcomes for maftivimab, and regulatory requirements.-Fineline Info & Tech
